English | Español

Bristol-Myers Squibb
Press release submission | Aug 9, 2020

BRISTOL-MYERS SQUIBB: Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

Press release submission | Feb 16, 2020

BRISTOL-MYERS SQUIBB: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Carol Ostrow | Dec 27, 2017

Restrictions on Opdivo combination trials for multiple myeloma treatment lifted by FDA
Carol Ostrow | Dec 27, 2017

Seattle Genetics, Bristol-Myers Squibb report Hodgkin treatment study interim results
Carol Ostrow | Dec 26, 2017

Bristol-Myers Squibb, Pfizer, others aim to raise awareness of stroke risk in atrial fibrillation patients
Robert Hadley | Nov 8, 2017

Europe agency approves expanded use of Bristol-Myers Squibb’s Opdivo to treat advanced melanoma
Carol Ostrow | Oct 14, 2017

Opdivo approved for treating certain liver cancer patients
Carol Ostrow | Oct 1, 2017

AbbVie, Bristol-Myers Squibb collaborate on anti-cancer regimen to target lung tumors

Trending
Patient Daily | Sep 3, 2025

Top healthcare marketing experts to present at AOCOO-HNS 2025 virtual mid-year symposium, led by Greg Caesar of Medfluence Advisors
+ Pharmaceuticals
Patient Daily | Sep 4, 2025

PhRMA CEO on 340B abuse: ‘Big hospitals are abusing the 340B program to markup medicine prices’
+ Pharmaceuticals
Patient Daily | Sep 2, 2025

Fmr. Gov. Dean on 340B: ‘There's no actual requirement for hospitals to pass along the savings’
+ Pharmaceuticals
Patient Daily | Aug 29, 2025

Deputy VP of Public Affairs of PhRMA on 340B: ‘Over 80% of all rural hospital beds were actually in urban hospitals’